Amylyx Pharmaceuticals announced Thursday it was withdrawing its approved treatment against the deadly neurodegenerative disease ALS after clinical data found no evidence the drug worked. The news follows data from a clinical trial of 664 ALS patients announced in March, which found no significant differences in outcomes between those on the treatment group and those who received a placebo.